We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Fibroblast growth factor-1 as a mediator of paracrine effects of canine adipose tissue-derived mesenchymal stem cells on in vitro-induced insulin resistance models.
- Authors
Kim, Hyeon-Jin; Li, Qiang; Song, Woo-Jin; Yang, Hye-Mi; Kim, Su-Yeon; Park, Sang-Chul; Ahn, Jin-Ok; Youn, Hwa-Young
- Abstract
Background: In the field of diabetes research, many studies on cell therapy have been conducted using mesenchymal stem cells. This research was intended to shed light on the influence of canine adipose-tissue-derived mesenchymal stem cell conditioned medium (cAT-MSC CM) on in vitro insulin resistance models that were induced in differentiated 3T3-L1 adipocytes and the possible mechanisms involved in the phenomenon. Results: Gene expression levels of insulin receptor substrate-1 (IRS-1) and glucose transporter type 4 (GLUT4) were used as indicators of insulin resistance. Relative protein expression levels of IRS-1 and GLUT4 were augmented in the cAT-MSC CM treatment group compared to insulin resistance models, indicating beneficial effects of cAT-MSC to DM, probably by actions of secreting factors. With reference to previous studies on fibroblast growth factor-1 (FGF1), we proposed FGF1 as a key contributing factor to the mechanism of action. We added anti-FGF1 neutralizing antibody to the CM-treated insulin resistance models. As a result, significantly diminished protein levels of IRS-1 and GLUT4 were observed, supporting our assumption. Similar results were observed in glucose uptake assay. Conclusions: Accordingly, this study advocated the potential of FGF-1 from cAT-MSC CM as an alternative insulin sensitizer and discovered a signalling factor associated with the paracrine effects of cAT-MSC.
- Subjects
DIABETES; FIBROBLAST growth factors; ADIPOSE tissues; MESENCHYMAL stem cells; INSULIN resistance
- Publication
BMC Veterinary Research, 2018, Vol 14, Issue 1, p1
- ISSN
1746-6148
- Publication type
Article
- DOI
10.1186/s12917-018-1671-1